Table 2 Selective Actively Recruiting Clinical Trials for patients
From: Underlying mechanisms and drug intervention strategies for the tumour microenvironment
Name of study Clinical | Phase | Conditions | Therapy | Measure | Clinicaltrials.gov Identifier |
|---|---|---|---|---|---|
A Study of ALKS 4230 on the TME | Phase 2 | Advanced Solid cancer | ALKS 4230 + pembrolizumab | Total T cells, CD8+ T cells, CD56+ cells and Treg cells | NCT04592653 |
Effects of MK-3475 (Pembrolizumab) on the Breast TME in Triple Negative Breast Cancer | Â | Triple Negative Breast Cancer | Merck 3475 Pembrolizumab | Number of subjects with significant mean percent change in TILs | NCT02977468 |
Analysis of the Modulation of the TME by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS) | Phase 2 | Metastatic Melanoma Naive to Immune Therapy in Metastatic Setting | Pembrolizumab - additional treatment | Bioinformatics | NCT03534635 |
GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer | Phase 2 | Pancreatic Cancer | Cyclophosphamide | CD8 count (cells/mm^3) in the TME | NCT03161379 |
L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer | Phase 1/Phase 2 | Pancreas Cancer | L-DOS47 Plus Doxorubicin | Cancer pH, Proportion of patients expressing anti-L-DOS47 antibodies | NCT04203641 |